Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The interaction between halofenate and propranolol

D H Huffman, D L Azarnoff, D W Shoeman

    Clinical Pharmacology and Therapeutics
    |June 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

    Journal of pharmacokinetics and biopharmaceutics·2010
    Same author

    Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years.

    International journal of clinical practice·2008
    Same author

    Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.

    International journal of clinical practice·2003
    Same author

    Protection of superoxide-induced cholesterol oxidation by antioxidants in protic conditions.

    International journal of food sciences and nutrition·2002
    Same author

    Ethical, medical and legal issues for the use of placebos in future lipid intervention trials.

    Current opinion in lipidology·2002
    Same author

    Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.

    Clinical cardiology·2001
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Halofenate significantly reduced plasma propranolol concentration and beta-adrenergic blockade in a double-blind study. This finding suggests a potential drug interaction affecting propranolol efficacy.

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine

    Background:

    • Propranolol is a beta-adrenergic blocker used for various cardiovascular conditions.
    • Understanding drug interactions is crucial for patient safety and treatment efficacy.

    Purpose of the Study:

    • To investigate the effect of halofenate on the beta-adrenergic blockade induced by propranolol.
    • To assess changes in plasma propranolol concentration during co-administration with halofenate.

    Main Methods:

    • A randomized, double-blind study was conducted involving 4 subjects.
    • Subjects received chronic drug administration of halofenate or placebo.

    Main Results:

    • Plasma propranolol concentration was significantly lower when co-administered with halofenate compared to placebo.

    Related Experiment Videos

  • The reduction in propranolol levels correlated with a decrease in beta-adrenergic blockade.

    • Conclusions:

    • Halofenate may decrease plasma concentrations of propranolol.
    • The underlying mechanism for this interaction requires further investigation.